Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Post by morningstar4on Jul 15, 2016 9:03am

329 Views

Post# 25055201

the juwel...

"Acasti has made important progress this quarter
We expect to have a clear view of our path forward by the end of this year".

3 mil in losses/quarter
They had revenue of $2000.- last quarter.!!!! I dont think anybody is pushing the Omemia.
What are the doing all day.

There does not seem to be any urgency....to have a clear view by end of the year? LOL
Its like a Government outfit.

Was the juwel of Neptune, now a money-pit and adrift...."clear view end of the year". LOL

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!